Handelsavisen
prelaunch
Companies ›Healthcare ›TECH.DH
TE
TECH.DH — — Pharmaceuticals

Techno Drugs Ltd

—
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
2,82 %
Op margin
18,8 %
ROE
—
Net margin
9,2 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$70,83
Open
—
Next earnings
2026-08-09
Ex-dividend
—
TR 1Y
—
About

Techno Drugs Ltd is a pharmaceutical company that develops and commercializes prescription drugs, generating revenue primarily through the sale of its branded and generic pharmaceutical products.

Business. Techno Drugs Ltd (TECH.DH) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD17 analysts
5 buy12 hold0 sell
Avg 12m price target69,52

Analyst recommendations

17 analysts · consensus Hold
Buy5
Hold12
Sell0
12-month price target
69,52
Consensus of sell-side coverage.
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
17 analysts · indicative
Ownership→
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TECH.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TECH.DH. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Techno Drugs Ltd (TECH.DH) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Techno Drugs Ltd has a capital structure characterized by a net income of BDT 100.38 million and an operating cash flow of BDT 115.47 million, indicating positive cash generation from operations. However, the company reported a capital expenditure of BDT -123.42 million, which suggests a net outflow from investing activities. The liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

    In terms of profitability, the company reported a gross profit of BDT 444.28 million and an operating income of BDT 205.84 million, translating to a gross margin of 40.5% and an operating margin of 18.8%. These figures are in line with the industry's typical profitability metrics, though specific cohort medians are not available for direct comparison.

    The company's revenue is concentrated in a single business segment, as disclosed in the latest financial report, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks, particularly in the pharmaceutical sector, where regulatory and market dynamics can vary significantly by region.

    Looking ahead, the company's growth trajectory is not quantified in the available data, as no outlook figures or revenue projections are provided. The absence of forward-looking guidance limits the ability to assess future performance or strategic direction.

    The risk assessment indicates a low dilution potential, with no evidence of recent share issuance or dilutive events. However, the liquidity risk remains unassessed, and the company's reliance on operating cash flow without a clear balance-sheet position introduces uncertainty regarding its ability to meet short-term obligations.

    Recent financial filings and transcripts are not available in the source documents, limiting the ability to identify specific events or strategic initiatives that may impact the company's performance. The absence of detailed disclosures also restricts the analysis of management commentary or investor relations updates.

    Key takeaways
    • Techno Drugs Ltd generates revenue through the sale of branded and generic pharmaceutical products.
    • The company has a gross margin of 40.5% and an operating margin of 18.8%, indicating strong profitability.
    • Capital expenditures are negative, suggesting a net outflow from investing activities.
    • The company's liquidity risk remains unassessed due to the absence of balance-sheet data.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    —
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    115.0%
    CapEx / revenueⓘ
    -11.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships11 disclosed relationships · 2 types · extracted from filings & disclosures
    Subsidiaries10
    EX21:36d9968f1cc3EX21:36d9968f1cc3Subsidiarie97%
    EX21:4b5fa109161fEX21:4b5fa109161fSubsidiarie97%
    EX21:50dc0f6380e1EX21:50dc0f6380e1Subsidiarie97%
    EX21:65ace40d7bb9EX21:65ace40d7bb9Subsidiarie97%
    EX21:6964b598c4bbEX21:6964b598c4bbSubsidiarie97%
    EX21:7e213b74e51cEX21:7e213b74e51cSubsidiarie97%
    EX21:84e81d11d535EX21:84e81d11d535Subsidiarie97%
    EX21:a4016064866fEX21:a4016064866fSubsidiarie97%
    EX21:eb35c358884aEX21:eb35c358884aSubsidiarie97%
    EX21:fd118f0d1e3bEX21:fd118f0d1e3bSubsidiarie97%

    Supply chain

    Vendors → TECH ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSTECHTECHTechno Drugs Ltd11 entitiesThermo Fisher ScientifAdvanced Medical EquipmeUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,92
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    17
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    revision ratio -0,00 · as of 2026-07-06 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-22 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$50,00
    Mean$69,52
    Median$73,00
    High$79,00
    Spot—
    12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    Op Margin18,8 %Above P75
    Net Margin9,2 %Above median
    Capex / Rev-11,3 %Below median
    Cash Conv1,15Above median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-22 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 322 543 sh18 exercises · 10 grants13 insiders
    • Hippel JamesCFO · Stock Options (Right to Buy) → Common StockDisposed 62 068 @ $47,60exercise · 2026-07-29
    • Kelderman KimDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 35 000 @ $47,60exercise · 2026-07-28
    • Bohnen ShaneSVP - General Counsel · Stock Option (Right to Buy) → Common StockDisposed 448 @ $47,60exercise · 2026-07-23
    • Crouse Steven C.President - Diag & Spatial Bi · Restricted Stock Units → Common StockDisposed 600exercise · 2026-06-02
    • Herr Amy E.Director · Stock Option (Right to Buy) → Common StockDisposed 6 636 @ $47,60exercise · 2026-05-08
    • Kelderman KimDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 26 692 @ $47,60exercise · 2026-05-05
    • Hippel JamesCFO · Stock Options (Right to Buy) → Common StockDisposed 62 000 @ $47,60exercise · 2026-05-05
    • Bohnen ShaneSVP - General Counsel · Stock Option (Right to Buy) → Common StockDisposed 8 400 @ $47,60exercise · 2026-05-05
    • Crouse Steven C.President - Diag & Spatial Bi · Restricted Stock Units → Common StockDisposed 794exercise · 2026-05-01
    • Kelderman KimDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 11 344 @ $47,60exercise · 2026-04-22
    • Hippel JamesCFO · Stock Options (Right to Buy) → Common StockDisposed 62 000 @ $47,60exercise · 2026-04-22
    • Kelderman KimDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 36 500 @ $47,60exercise · 2026-04-14
    • Bohnen ShaneSVP - General Counsel · Restricted Stock Units → Common StockDisposed 2 259exercise · 2026-04-03
    • Crouse Steven C.President - Diag & Spatial Bi · Stock Option (right to buy) → Common StockAcquired 1 911 @ $57,82grant · 2026-03-02
    • Crouse Steven C.President - Diag & Spatial Bi · Restricted Stock Units → Common StockAcquired 735grant · 2026-03-02
    • Crouse Steven C.President - Diag & Spatial Bi · Performance Restricted Stock Units → Common StockAcquired 2 387grant · 2026-03-02
    • Herr Amy E.Director · Restricted Stock Units → Common StockDisposed 38exercise · 2026-02-03
    • McManus MatthewPresident - Diag & Spatial Bio · Restricted Stock Units → Common StockDisposed 4 621exercise · 2026-02-01
    • Hippel JamesCFO · Restricted Stock Units → Common StockDisposed 11 545exercise · 2025-11-03
    • Hippel JamesCFO · Restricted Stock Units → Common StockDisposed 13 159exercise · 2025-11-03
    • Geist WilliamPRESIDENT, PROTEIN SCIENCES · Restricted Stock Units → Common StockDisposed 9 911exercise · 2025-11-03
    • Bushman Julie LDirector · Stock Options (Right to Buy) → Common StockAcquired 3 777 @ $60,96grant · 2025-10-30
    • KEEGAN JOSEPH DDirector · Stock Options (Right to Buy) → Common StockAcquired 3 777 @ $60,96grant · 2025-10-30
    • HIGGINS JOHN LDirector · Stock Options (Right to Buy) → Common StockAcquired 3 777 @ $60,96grant · 2025-10-30
    • Seth AlpnaDirector · Stock Options (Right to Buy) → Common StockAcquired 3 777 @ $60,96grant · 2025-10-30

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Capex To Revenue
      capital_expenditure / revenue
    Source documents
    • Techno Drugs Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,07 %$197M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,05 %$268M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,05 %$67M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,04 %$86M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,04 %$130M
    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,04 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,04 %$240M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,03 %$160M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,03 %$446M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,02 %$1 074M
    • FMR LLCInstitutional Investor · as of 2026-03-310,02 %$413M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,02 %$103M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,02 %$89M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,02 %$39M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,02 %$92M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,02 %$267M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,02 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,02 %$32M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,02 %$1 047M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$102M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$86M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$307M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,01 %$34M
    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,01 %$19M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$69M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$24M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$18M
    • Jennison Associates LLCInvestment Managers · as of 2026-03-310,00 %$6M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$5M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$13M
    • Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,00 %$16M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$4M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$4M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 2 sellsnet -$437K13 insiders · last 365d
    • Hippel JamesCFO · Common StockOther 62 068 @ $47,60$3,0M · 2026-07-29
    • Hippel JamesCFO · Common StockOther 51 024 @ $72,03$3,7M · 2026-07-29
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 35 000 @ $47,60$1,7M · 2026-07-28
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 28 686 @ $72,07$2,1M · 2026-07-28
    • Bohnen ShaneSVP - General Counsel · Common StockOther 448 @ $47,60$21K · 2026-07-23
    • Bohnen ShaneSVP - General Counsel · Common StockOther 344 @ $71,77$25K · 2026-07-23
    • Crouse Steven C.President - Diag & Spatial Bi · Common StockOther 600 · 2026-06-02
    • Crouse Steven C.President - Diag & Spatial Bi · Common StockOther 216 @ $49,77$11K · 2026-06-02
    • Herr Amy E.Director · Common StockOther 6 636 @ $47,60$316K · 2026-05-08
    • Herr Amy E.Director · Common StockSold 6 636 @ $48,28$320K · 2026-05-08
    • Hippel JamesCFO · Common StockOther 62 000 @ $47,60$3,0M · 2026-05-05
    • Hippel JamesCFO · Common StockOther 56 955 @ $56,68$3,2M · 2026-05-05
    • Bohnen ShaneSVP - General Counsel · Common StockOther 8 400 @ $47,60$400K · 2026-05-05
    • Bohnen ShaneSVP - General Counsel · Common StockOther 7 055 @ $56,68$400K · 2026-05-05
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 26 692 @ $47,60$1,3M · 2026-05-05
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 23 951 @ $56,68$1,4M · 2026-05-05
    • Crouse Steven C.President - Diag & Spatial Bi · Common StockOther 794 · 2026-05-01
    • Crouse Steven C.President - Diag & Spatial Bi · Common StockOther 311 @ $55,02$17K · 2026-05-01
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 11 344 · 2026-04-22
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 1 363 @ $58,58$80K · 2026-04-22
    • Hippel JamesCFO · Common StockOther 62 000 · 2026-04-22
    • Hippel JamesCFO · Common StockOther 56 097 @ $58,58$3,3M · 2026-04-22
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 32 088 @ $58,66$1,9M · 2026-04-14
    • Kelderman KimDirector, Chief Executive Officer · Common StockOther 36 500 · 2026-04-14
    • Bohnen ShaneSVP - General Counsel · Common StockOther 2 259 · 2026-04-03

    Short positioning

    12.1Mshares short-23.8% vs prior
    2.27days to cover
    8.7%short of daily vol
    253.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)
    Index membership
    S&P 500United States

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TECH.DHCanonical
    — · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00M&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown
    Relationship graph
    TECHTMO.OEX21:36dEX21:4b5EX21:50dEX21:65aEX21:696EX21:7e2EX21:84eEX21:a40EX21:eb3Pharmaceutical
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -2.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 4.54xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -3.2%Derived (calculated)
    • Total assets (annual): USD 2.52BSEC XBRL filing
    • Current assets (annual): USD 637.43MSEC XBRL filing
    • Current liabilities (annual): USD 140.43MSEC XBRL filing
    • Shares outstanding (annual): 155.88MSEC XBRL filing
    • Shareholders' equity (annual): USD 2.01BSEC XBRL filing
    • Cash & equivalents (annual): USD 172.88MSEC XBRL filing
    • Net margin (FY 2025-06-30): 6.0%Derived (calculated)
    • Gross margin (FY 2025-06-30): 64.8%Derived (calculated)
    • Capex (YoY) (2025-06-30 vs 2024-06-30): -50.7%Derived (calculated)
    • Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): 10.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): -56.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): -56.2%Derived (calculated)
    • Gross profit (YoY) (2025-06-30 vs 2024-06-30): 2.7%Derived (calculated)
    • Net income (YoY) (2025-06-30 vs 2024-06-30): -56.3%Derived (calculated)
    • Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -3.8%Derived (calculated)
    • Operating income (YoY) (2025-06-30 vs 2024-06-30): -50.5%Derived (calculated)
    • Revenue (YoY) (2025-06-30 vs 2024-06-30): 5.2%Derived (calculated)
    • EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Operating income (annual): USD 102.25MSEC XBRL filing
    • Gross profit (annual): USD 790.27MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    2026-08-04 06:05 UTCSAGATech Market Volatility Speculative bets on GameStop-eBay merger fade as OpenAI's IPO prospects and European infrastructure concerns drive shifting investor sentiment.
    2026-07-29INSIDERHippel James transacted 62.1k sh — CFO ~$2.95M
    2026-07-29INSIDERHippel James transacted 51.0k sh — CFO ~$3.68M
    2026-07-29INSIDERHippel James disposed of 62.1k sh Stock Options (Right to Buy) — CFO
    2026-07-28INSIDERKelderman Kim transacted 35.0k sh — Director, Chief Executive Officer ~$1.67M
    2026-07-28INSIDERKelderman Kim transacted 28.7k sh — Director, Chief Executive Officer ~$2.07M
    2026-07-28INSIDERKelderman Kim disposed of 35.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    2026-07-23INSIDERBohnen Shane transacted 448 sh — SVP - General Counsel ~$21k
    2026-07-23INSIDERBohnen Shane transacted 344 sh — SVP - General Counsel ~$25k
    2026-07-23INSIDERBohnen Shane disposed of 448 sh Stock Option (Right to Buy) — SVP - General Counsel
    2026-07-06 07:32 UTCNEWSNovartis to acquire UK biotech Myricx Bio for $1.5 billion → The Swiss pharma giant expands its pipeline with a cash deal for the UK-based firm, expected to close in the second half of 2026.
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-27 03:14 UTCHOLDERInstitutional holding changed
    2026-06-27 03:14 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-25 17:42 UTCNEWSMerck to acquire Bio-Techne in $11.3 billion life-sciences expansion → The DAX-listed chemical giant secures a major foothold in the US research tools market, signaling aggressive growth beyond its core pharma business.
    2026-06-25 11:40 UTCNEWSMerck KGaA to acquire Bio-Techne in $11.3 billion life-sciences deal → The German chemical giant expands its research tools portfolio with a major US biotech acquisition, signaling aggressive consolidation in the life-sciences sector.
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-02 00:00 UTCINSIDER3 insider transactions — 2026-06 1 derivative
    2026-06-02 00:00 UTCINSIDER3 insider transactions — 2026-06 1 derivative
    2026-06-02INSIDERCrouse Steven C. transacted 600 sh — President - Diag & Spatial Bi
    2026-06-02INSIDERCrouse Steven C. transacted 216 sh — President - Diag & Spatial Bi ~$11k
    2026-06-02INSIDERCrouse Steven C. disposed of 600 sh Restricted Stock Units — President - Diag & Spatial Bi
    2026-05-21 05:24 UTCFILINGRegulatory filing →
    2026-05-08 00:00 UTCINSIDER15 insider transactions — 2026-05 · net sell $386k 5 derivative
    2026-05-08 00:00 UTCINSIDER15 insider transactions — 2026-05 · net sell $386k 5 derivative
    2026-05-08INSIDERHerr Amy E. transacted 6.6k sh — Director ~$316k
    2026-05-08INSIDERHerr Amy E. sold 6.6k sh — Director ~$320k
    2026-05-08INSIDERHerr Amy E. disposed of 6.6k sh Stock Option (Right to Buy) — Director
    2026-05-06FILING10-Q filing →
    2026-05-06FILING8-K filing →
    2026-05-05INSIDERHippel James transacted 62.0k sh — CFO ~$2.95M
    2026-05-05INSIDERHippel James transacted 57.0k sh — CFO ~$3.23M
    2026-05-05INSIDERBohnen Shane transacted 8.4k sh — SVP - General Counsel ~$400k
    2026-05-05INSIDERBohnen Shane transacted 7.1k sh — SVP - General Counsel ~$400k
    2026-05-05INSIDERKelderman Kim transacted 26.7k sh — Director, Chief Executive Officer ~$1.27M
    2026-05-05INSIDERKelderman Kim transacted 24.0k sh — Director, Chief Executive Officer ~$1.36M
    2026-05-05INSIDERKelderman Kim disposed of 26.7k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
    Showing the 40 most recent of 84 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage